Cardiol Therapeutics Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Completed patient enrollment in the phase ii maveric-pilot study evaluating cardiolrx™ in patients withrecurrent pericarditis, with topline results expected in q2 2024 cardiolrx™ granted u.s. fda orphan drug designation for the treatment of pericarditis,which includes recurrent pericarditis exceeded 50% enrollment in the phase ii archer trial evaluating cardiolrx™in patients with acute myocarditis; study expected to reach full enrollment during q3 2024 data presented at the hfsa annual scientific sessions 2023 demonstrated that the api in cardiol's novelcrd-38 formulation attenuates harmful fat distribution and key markers of cardiac inflammation andremodelling in a model of heart failure with preserved ejection fraction cash and cash equivalents of $34...

Topline results expected in q2 2024 this is a designated news release. toronto, ontario--(newsfile corp. - february 21, 2024) - cardiol therapeutics inc. (nasdaq: crdl) (tsx: crdl) ("cardiol" or the "company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced completion of patient enrollment in its phase ii open-label pilot study ("maveric-pilot") investigating the safety, tolerability, and efficacy of cardiolrx™ in patients with recurrent pericarditis.

Designation based on pre-clinical data and initial clinical data from the company's maveric-pilot phase ii study this is a designated news release. toronto, ontario--(newsfile corp. - february 15, 2024) - cardiol therapeutics inc. (nasdaq: crdl) (tsx: crdl) ("cardiol" or the "company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the united states food and drug administration ("fda") has granted orphan drug designation ("odd") for the company's lead small molecule drug candidate for the treatment of pericarditis, which includes recurrent pericarditis.

Toronto, ontario--(newsfile corp. - january 24, 2024) - cardiol therapeutics inc. (nasdaq: crdl) (tsx: crdl) ("cardiol" or the "company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced that it received notice on january 23, 2024 from the nasdaq stock market llc ("nasdaq") stating that the company has regained compliance with the minimum bid price requirement under nasdaq listing rule 5550(a)(2) ("minimum bid requirement") for continued listing on the nasdaq capital market. accordingly, the company is now in compliance with all applicable listing standards.

Toronto, ontario--(newsfile corp. - january 9, 2024) - cardiol therapeutics inc. (nasdaq: crdl) (tsx: crdl) ("cardiol" or the "company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it has exceeded 50% patient enrollment for archer, the company's phase ii, multi-center, international, double-blind, randomized, placebo-controlled trial investigating the safety, tolerability, and impact of cardiolrx™ on myocardial recovery in patients presenting with acute myocarditis. "achieving this milestone reflects the commitment and interest demonstrated by our clinical collaborators and participating patients, and we thank them for their contribution to the progress being made in this important clinical trial," said david elsley, cardiol therapeutics' president and chief executive officer.

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) said it had made significant strides in 2023 and early 2024 to advance its offerings of novel therapeutic solutions to patients with underserved heart diseases. In an operational update looking at the 2023 calendar year, CEO David Elsley highlighted some of the main milestones the company achieved.

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) said it had made significant strides in 2023 and early 2024 to advance its offerings of novel therapeutic solutions to patients with underserved heart diseases. In an operational update looking at the 2023 calendar year, CEO David Elsley highlighted some of the main milestones the company achieved.

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) has reached a significant milestone in its mission to combat heart disease. The company has wrapped up patient enrollment for its Phase II open-label pilot study, known as MAvERIC-Pilot, which focuses on patients suffering from recurrent pericarditis.

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) made headlines earlier in the week when it revealed that the US Food and Drug Administration had granted its lead drug candidate CardiolRx orphan drug designation, indicating potential efficacy in treating recurrent pericarditis. The designation provides benefits such as marketing exclusivity and fee reduction, and the company's share prices have surged as a result.

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL), the pharmaceutical company, has been awarded Orphan Drug Designation for its lead drug candidate. The US Food and Drug Administration (FDA) awarded Cardiol the orphan status for the drug due to its potential use in helping treat both one-time and recurrent pericarditis, the inflammation of the lining around the heart.

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) told investors it has exceeded 50% patient enrollment for its Phase II ARCHER trial. The multi-center, international, double-blind, randomized, placebo-controlled trial is investigating the safety, tolerability, and impact of CardiolRx on myocardial recovery in patients presenting with acute myocarditis.

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) has added Massachusetts General to the enrollment process for the MAvERIC-Pilot, a Phase II open-label pilot study of lead candidate CardiolRx in patients suffering from recurrent pericarditis. The renowned Mass General, recognized for its top-notch medical research programs, joins eight other leading medical research centers in the United States dedicated to pericarditis care.

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced that study results have demonstrated an experimental model of pericarditis induces mesothelial to mesenchymal transition (MMT) and that this process is inhibited by cannabidiol treatment, the active pharmaceutical ingredient in its lead candidate, CardiolRx. The study results were presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases (MPD2023), held on November 15 and 16, 2023, in Belgrade, Serbia.

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced it has successfully enrolled over 50% of the targeted number of patients for its Phase II open-label pilot study on its lead candidate CardiolRx. The primary objective of the MAvERIC-Pilot study is to assess the safety, tolerability, and efficacy of CardiolRx in patients with recurrent pericarditis, a rare and debilitating inflammatory heart disease is known for negatively impacting the quality of life and physical well-being of those affected.

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) has reported positive study results showing that cannabidiol, the active pharmaceutical ingredient in the company's novel CRD-38 subcutaneous (SUBQ) formulation, reduces harmful fat distribution and key markers of cardiac inflammation and remodeling. Study results from one of Cardiol's international collaborating research centers demonstrated that subcutaneously administered cannabidiol slowed increases in body weight and heart weight, and prevented increases in key cardiac inflammatory and remodelling markers in a model of heart failure with preserved ejection fraction (HFpEF).